Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $66,367.66 in Stock

Share on StockTwits

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 4,318 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $15.37, for a total transaction of $66,367.66. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Patrick J. Haley also recently made the following trade(s):

  • On Wednesday, February 19th, Patrick J. Haley sold 5,000 shares of Exelixis stock. The stock was sold at an average price of $22.00, for a total transaction of $110,000.00.

EXEL stock opened at $15.77 on Thursday. The stock has a market capitalization of $4.84 billion, a price-to-earnings ratio of 15.46, a PEG ratio of 1.46 and a beta of 1.41. Exelixis, Inc. has a 1 year low of $13.67 and a 1 year high of $25.20. The stock’s fifty day moving average is $18.40 and its two-hundred day moving average is $17.84.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 25th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.07. The company had revenue of $240.31 million for the quarter, compared to analysts’ expectations of $240.49 million. Exelixis had a return on equity of 20.83% and a net margin of 33.17%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $0.37 earnings per share. Analysts predict that Exelixis, Inc. will post 0.56 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of EXEL. Amundi Pioneer Asset Management Inc. raised its stake in shares of Exelixis by 182.1% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 176,193 shares of the biotechnology company’s stock valued at $4,193,000 after purchasing an additional 113,733 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Exelixis by 4.7% during the third quarter. Russell Investments Group Ltd. now owns 53,200 shares of the biotechnology company’s stock valued at $940,000 after purchasing an additional 2,409 shares in the last quarter. Colony Group LLC raised its stake in shares of Exelixis by 4.1% during the third quarter. Colony Group LLC now owns 130,200 shares of the biotechnology company’s stock valued at $2,303,000 after purchasing an additional 5,140 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Exelixis by 3.1% during the third quarter. Voya Investment Management LLC now owns 283,322 shares of the biotechnology company’s stock valued at $5,010,000 after purchasing an additional 8,551 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Exelixis by 2.9% during the third quarter. State Street Corp now owns 10,450,777 shares of the biotechnology company’s stock valued at $184,822,000 after purchasing an additional 298,036 shares in the last quarter. Institutional investors own 78.64% of the company’s stock.

Several brokerages recently issued reports on EXEL. Bank of America restated a “buy” rating and set a $21.00 price objective (down from $22.00) on shares of Exelixis in a research note on Monday, January 13th. Zacks Investment Research cut Exelixis from a “buy” rating to a “hold” rating and set a $20.00 price objective on the stock. in a research note on Friday, January 10th. Barclays began coverage on Exelixis in a research note on Wednesday, March 4th. They set an “overweight” rating and a $26.00 price objective on the stock. ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. Finally, Stifel Nicolaus raised their price objective on Exelixis from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $25.17.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: How to calculate the intrinsic value of a stock

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.